Puneet Varma (Editor)

Bradley Pharmaceuticals

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Industry
  
Pharmaceuticals

Revenue
  
US$145 million (2006)

Founder
  
Daniel Glassman

Successor
  
Nycomed

Type of business
  
Merged

Key people
  
Daniel Glassman (CEO)

Website
  
www.bradpharm.com

Founded
  
1985

Number of employees
  
300

Products
  
Adoxa, Zoderm, Pamine Forte, Kerol

Headquarters
  
Fairfield, New Jersey, United States

Bradley Pharmaceuticals was a pharmaceutical company headquartered in Fairfield Township, Essex County, New Jersey. The company was founded in 1985 by Daniel Glassman who was also its CEO.

Contents

The company marketed to niche physician specialties in the U.S. and 38 international markets. Bradley Pharmaceuticals comprised Doak Dermatologics, specialized in therapies for dermatology and podiatry; Kenwood Therapeutics, providing gastroenterology, OB/GYN and other internal medicine brands; and A. Aarons, which markets authorized generic versions of Doak and Kenwood therapies.

Doak Dermatologics

Doak Dermatologics was the division of Bradley Pharmaceuticals that marketed products to dermatologists. Its flag products were Zoderm which is a topical anti-acne product. Adoxa (doxycycline) was an antibiotic intended to treat mild to severe acne.

Kenwood Therapeutics

Kenwood was the affiliate brand that worked with therapeutic products. Among the most prescribed ones were Entsol which is a respiratory therapeutic product and Pamine which is intended to treat digestive problems.

Public trading

The company was publicly traded at the NYSE by its code BDY since May 2003.

Nycomed Merger

Bradley Pharmaceuticals merged with Nycomed, a European company. The merger was completed on February 21, 2008, and Bradley became an integral part of Nycomed.

References

Bradley Pharmaceuticals Wikipedia